Form 4 for EWTX Edgewise Therapeutics, Inc.
Accepted 2024-09-24 00:00:00 ET · period of report 2024-09-20 · accession 0001562180-24-006946 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-24 | 2024-09-20+ | EWTX | MOORE JOHN R | GC | M - OptEx | $0.71 | +70.9K | 53.3K | New | +$50.4K |
| DM | 2024-09-24 | 2024-09-20+ | EWTX | MOORE JOHN R | GC | S - Sale+OE | $28.15 | -70.9K | 3,252 | -96% | -$2.00M |
| DM | 2024-09-24 | 2024-09-20+ | EWTX | MOORE JOHN R | GC | M - OptEx | $0.00 | -70.9K | 41.6K | -63% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-23 | M | A | 20,922 | $0.71 | 24,174 | D | — | — | |
| 2 | Common | Common Stock | 2024-09-23 | S | D | 20,922 | $27.63 | 3,252 | D | — | — | |
| 3 | Common | Common Stock | 2024-09-20 | S | D | 50,000 | $28.37 | 3,252 | D | — | — | |
| 4 | Common | Common Stock | 2024-09-20 | M | A | 50,000 | $0.71 | 53,252 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-09-20 | M | D | 50,000 | $0.00 | 62,558 | D | $0.71 · — to 2030-09-01 | 50,000 Common Stock | (F1) 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2024-09-23 | M | D | 20,922 | $0.00 | 41,636 | D | $0.71 · — to 2030-09-01 | 20,922 Common Stock | (F1) 1/4th of the shares subject to the option became vested and exercisable on September 1, 2021 and 1/48th of the shares subject to the option continue to vest each month, subject to the Reporting Person continuing as a service provider through each vest date. |